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Human ageing is associated with a significant decline in neuromuscular function 
and performance (Doherty et al, 1993a, Ross et al, 1997 and Vandervoort, 2002). The 
term sarcopenia was first used by Rosenberg (Rosenberg, 1989), to describe age 
associated loss of skeletal muscle mass. Sarcopenia is now generally used to describe 
age-associated changes that occur within skeletal muscle and thus include the effects of 
altered central and peripheral nervous system innervation, altered hormonal status, 
altered caloric and protein intake and inflammatory effects. All these contribute to 
sarcopenia and to the characteristic skeletal muscle atrophy and weakness, which are 
considered major contributing factors to the loss of functional mobility, independence and 
frailty present in many elderly (Roubenoff and Hughes, 2000; Roubenoff et al. 2001). 
Because our society is an ageing one, understanding the underlying mechanisms of 
sarcopenia is essential for the development of effective interventions to prevent disability 
and optimize quality of life in older people. This review will focus on the potential role of 
inflammatory factors in sarcopenia and on the effects of exercise interventions. 
 
 
1. Age related loss of skeletal muscle mass 
 
Several studies have reported total muscle cross sectional area (CSA) 
decreases around 40% between the ages of 20 and 60 years (Doherty et al. 1993a, 
Porter et al, 1995 and Vandervoot, 2002). Increases in non-muscle tissues (fat and 
connective tissue) have also been reported (Rice et al, 1989). Increases of 59% of non-
muscle tissue for the quadriceps and 127% for the hamstrings have been reported by 
Overend et al. (Overend et al., 1992a). CSA measurements from whole muscle obtained 
post-mortem showed reductions of 40% for subjects between 20 and 80 years old with 
an average reduction of 10% at 50 years accelerating thereafter (Lexell et al 1988). In a 
study measuring total appendicullar skeletal muscle mass (TASM) using dual –energy X-
ray absorptiometry (DEXA) the authors (Gallagher et al, 1997) found, after adjusting for 
factors like height, body weight and age, that men had larger TASM then women and 
showed larger age-related decreases in TASM (14,8 vs 10,8%) when compared to 
women. A study using whole body magnetic resonance imaging (MRI) to determine 
skeletal mass in a sample a 268 men and 200 women aged between 18 and 88 years 
old (Janssen et al, 2000), showed significantly more muscle mass in men in both 
absolute terms (33,0 vs. 21kg)  and relative to body mass (38,4 vs. 30,6%) after 
controlling for height and body mass,  with greater losses of muscle mass with ageing 
when compared to women. The reduction in skeletal muscle mass with age was greater 
in the lower body for both men and women with a noticeable decrease in skeletal muscle 
mass beginning at 45 years of age in both men and women. 
 
 
2. Age related loss of strength 
 
Not only age-related loss of muscle mass but also age-related loss of strength 
has been well established with cross sectional studies of limb muscles tested under 
isometric and dynamic conditions, usually comparing groups of healthy young, middle-
aged and older men and women (Doherty et al, 1993a; Porter et al, 1995; Vandervoort, 
2002). Studies comparing knee extensor strength (Larsson et al, 1979; Young et al, 
1984; Young et al, 1985; Overend et al, 1992b; Ivey et al, 2000) in groups of young and 
healthy older subjects (70-80 years of age) have on average reported age-related 
decreases in strength on the order of 20 to 40% with greater losses (50% or more) being 
reported for subjects in their ninth decade and beyond (Murray et al, 1980; Murray et al, 
1985).  
In general similar losses in strength have been reported for proximal and distal limb 
muscles (reviewed by Doherty, 2003a) with relative losses similar for men and women. 
Longitudinal studies have provided important information concerning the rate of strength 
decline with age (Bassey and Harries, 1993; Kallman et al, 1990). In the study by  
Bassey and Harries (Bassey and Harries, 1993) a 3% loss of grip strength per year for 
men and 5% for women over 4 years was reported while in a study with a large cohort 
(3680) of Japanese –American men (Rantanen et al, 1998) with a 27 year follow up a 
1% per year decline in grip strength was reported. It also showed a more significant rate 
of decline for those older at baseline or with chronic diseases like diabetes and arthritis. 
In general it appears that healthy men and women in their seventh and eight decades 
show, on average, 20-40% less strength compared with their younger counterparts. 
These losses are even greater (50% or more) for the very old.  
 
 
 
3. Mechanisms underlying sarcopenia 
 
Age-associated loss of muscle mass appears to be the most significant factor 
for age-associated loss of muscle strength (reviewed by Doherty, 2003c) and associated 
disability in older men and women. Histological data has provided some insight into the 
cause of age-related atrophy, mostly from needle biopsy sampling of the vastus lateralis 
muscle. Most studies report reductions in type II fiber size, the type I fiber size being a lot 
less affected with age (Lexell et al, 1988; Ross et al, 1997; Vandervoot, 2002). 
Reductions in type II fiber area range from 20 to 50%, type I fiber area losses range from 
1 to 25%. There is also histochemical evidence of fiber type grouping, fiber atrophy and 
increase coexpression of myosin heavy chain isoforms in the same fiber consistent with 
a progressive denervation and reinnervation process (Andersen et al, 1999; Oertel, 
1986). Taken together, these findings suggest that α-motoneuron loss may play an 
important role in age-related loss of muscle mass. Electrophysiological studies using 
either macro electromyographic techniques or motor unit number estimation techniques 
have found losses of whole functioning motor units in proximal and distal muscles in the 
upper and lower extremities (De Koning, 1988; Doherty and Brown, 2002; Stalberg et al 
1989). These studies are consistent with anatomic data that has demonstrated losses of 
anterior horn cells and ventral root fibers with aging (Doherty et al, 1993; Kawamura et 
al, 1977a; Kawamura et al, 1977b Mittal et al, 1987).  Cross sectional studies suggest 
that motoneuron or motor unit numbers are well maintained until the seventh decade and 
then begin to decline rapidly  (McComas, 1991; McComas 1998). 
Loss of muscle mass secondary to muscle fiber loss and secondarily to fiber 
atrophy appear largely responsible for sarcopenia. Hormonal, metabolic, nutritional and  
immunologic factors also contribute to sarcopenia ( reviewed by Roubenoff and Hughes, 
2000). It has been postulated that with aging there may be a withdrawal of, or resistance 
to anabolic factors and a shift towards catabolic processes in the muscle. 
 
 
 
4. Systemic low grade inflammation 
 
Ageing is associated with systemic low-grade inflammation and the elevation of 
basal circulating levels several cytokines (Reviwed by Krabbe et al, 2004). Systemic low 
grade inflammation has also been associated with decreased muscle mass (Ferrucci et 
al, 2002; Pedersen et al, 2003; Visser et al, 2002) as well as the development of 
functional disability in the elderly (Ferrucci et al, 1999).  
The local response to infections or tissue injury involves the production of cytokines that 
are released at the site of inflammation. Cytokines are small polypeptides, that have 
immunoregulatory roles. They facilitate the influx of lymphocytes, neutrophils, monocytes 
and other cells to the site of inflammation. The local inflammatory response is 
accompanied by a systemic response called the acute-phase response. This includes 
the production of a large number of acute phase proteins, such as C-Reactive Protein 
(CRP) and can be mimicked by the injection of the cytokines TNF-α, IL-1β and IL-6 into 
laboratory animals or humans (Akira et al, 1992; Akira et al, 1993; Dinarello, 1992). The 
first cytokines to appear in the cytokine cascade are TnF-α, IL-1β, IL-6, Il-1 receptor 
antagonist (IL-1ra), and soluble TNF-α receptors (sTNF-R). IL-1ra inhibits IL-1 signal 
transduction and sTNF-R are the naturally occurring TNF-α inhibitors (Akira et al, 1992; 
Akira et al, 1993; Dinarello, 1992). In response to acute infection or trauma, the 
cytokines and their inhibitors may increase several fold and decrease when the infection 
or trauma is resolved.  
Chronic low-grade systemic inflammation is used to describe conditions in which a two to 
threefold increase in the circulating concentrations of TNF-α, IL-1, IL-6, IL-1ra, sTNF-R 
and CRP occurs. In this case the stimuli for the cytokine production are not known, but it 
is assumed that the origin of TNF on chronic low-grade systemic inflammation is mainly 
the adipose tissue (Coppack, 2001; Hotamisligil, 1993). 
 
 
4. Age-associated  Increased levels of circulating cytokines 
 
With ageing, increased plasma levels of Il-6 (Wei et al, 1992; Ershler et al, 1993; 
Bruunsgaard et al 1999a; Hagger et al 1994), TNF-α (Bruunsgaard et al, 1999a; 
Bruunsgaard et al, 2000; Paolisso et al, 1998) , IL-1ra ( Dobbs et al, 1999), sTNF-R 
(Bruunsgaard et al, 1999; Catania et al, 1997) and CRP (Ballou et al, 1996) have been 
reported. These cytokines work in a network and their levels are found to intercorrelate, 
for example, plasma levels of TNF-α were positively correlated with IL-6, sTNF-R and 
CRP in centenarians with high levels of TNF-α but not IL-6 being associated with 
dementia and atherosclerosis (Bruunsgaard et al, 1999a).  Although some authors have 
reported no changes in IL-6 and TNF-α plasma levels with age (Fagiolo et al, 1993; 
Peterson et al 1994) it is possible that these discrepancies relate to the health status of 
the participants and to differences in their age. For example IL-6 but not TNF-α was 
increased in middle aged people whereas both cytokines were elevated in octogenarians 
(Bruunsgaard et al, 1999a). Inflammatory mediators also act as disease markers and 
levels were higher in randomly selected subjects (Bruunsgaard et al, 1999a; Di Iorio et 
al, 2003, Ferrucci et al , 1999) compared to very healthy elderly individuals (Baggio et al, 
1998) selected in accordance with the SENIEUR protocol. A larger consensus seems to 
exist regarding the anti-inflammatory mediators (IL-1ra and sTNF-R) acute phase 
proteins (CRP), sIL-2R  and neutrophils with circulating levels and numbers increased in 
elderly populations (Ballou et al, 1996; Cakman et al, 1997; Catania et al, 1997; Gerli et 
al 2000; Rea et alL, 1996). Increases in inflammatory markers are in the order of 2-4 fold 
and thus far from the increases observed during acute infection. 
 
 
 
5. Effects of inflammatory mediators in age-associated chronic diseases. 
 
Elevated levels of inflammatory mediators have been associated with several disorders 
namely the metabolic syndrome, Type 2 diabetes, atherosclerosis, cardiovascular 
disease and dementia (Alvarez et al, 1996; Barzilay et al, 2001; Duncan et al, 2003; 
Festa et al, 2002; Ford, 2002; Han et al, 2002; Hofman et al, 1997; Pradhan et al, 2001).  
Atherosclerotic plaques contain smooth muscle cells, macrophages and activated T 
lymphocytes and it is widely accepted that this pathology results from an inflammatory 
response to injuries in the vessel walls and endothelial dysfunction caused by factors like 
oxidised low-density lipoprotein (LDL), diabetes mellitus, hypertension, free radicals 
induced by smoking, infectious agents and a combination of these and other factors. The 
activated endothelial cells are targets as well as sources of inflammatory cytokines and 
chemokynes that induce upregulation of adhesion molecules and promote leucocyte 
migration across the endothelial wall. Several studies have linked systemic low grade 
inflammation in elderly population to the prevalence and prognosis of cardiovascular 
disease. For example, plasma levels of TNF-α have been correlated with dyslipidemia 
and a high prevalence of cardiovascular disease in 80 year old subjects (Bruunsgaard et 
al, 2000). TNF-α was also correlated with the blood pressure, insulin resistence, levels of 
cellular adhesion proteins and common carotid intimamedia thickness in healthy middle-
aged men (Sloog et al, 2002). IL-1β serum levels were associated with congestive heart 
failure, angina and a history of dyslipidemia in 1292 subjects (Di Iorio et al, 2003). 
Circulating IL-6 levels acted as a marker of subclinical cardiovascular disease in a case 
control study of elderly people (Jenny et al, 2002) and was a predictor of mortality related 
to cardiovascular disease in a group of 65+ years old (Harris et al, 1999). IL-6 was also 
shown to be a predictor of myocardial infarcts in healthy middle-aged men (Ridker et al, 
2000). IL-1β, TNF-α and IL-6 induce the production of CRP, which as been shown to be 
a strong predictor of coronary events in several studies (reviewed in Pepys and 
Hirschfield, 2003).  
It has been widely assumed that systemic low grade inflammation in cardiovascular 
disease is caused by the inflammation within the atheromatous lesions but now scientists 
are wondering if atherosclerosis could be a consequence of systemic low-grade 
inflammation. Chronic systemic non-vascular inflammation is known to be 
proatherogenic in general and acute systemic inflammatory episodes are strongly 
associated with atherothrombotic events (Jones et al, 2001). Also some studies have 
shown that systemic low-grade inflammation has the potential to induce several risk 
factors for cardiovascular disease: TNF-a induces insulin resistance and impairs the 
endothelium upreguralion of adhesion molecules (Bruunsgaard and Pedersen, 2003). 
Both TNF-α and IL-6 affect the coagulation system and lipid metabolism, causing a 
procoagulant state and dyslipidemia (Bruunsgaard and Pedersen, 2003).  
Inflammatory mechanisms have also been linked to age-associated cognitive decline, 
including Alzeimer’s Disease and vascular dementia (Hofman et al, 1997) and to 
depression in aged subjects (Penninx et al 2003). In a study with centenarians, plasma 
TNF-α was shown to be associated with dementia (Bruunsgaard et al, 1999a). Increased 
plasma levels of  IL-1β have also been reported in patients with Alzeimer’s disease 
(Licastro et al, 2000; Alvarez et al, 1996). Studies on autopsy specimens have found a 
marked over expression of IL-1 (Griffin et al, 1989) and IL-6 (Bauer et al, 1991) in the 
brains of Alzeimer’s disease patients. Elevated levels of TNF (increases in 25-fold) have 
also been found in cerebrospinal fluid (Tarkowski et al, 2003) of patients with Alzeimer’s 
disease. Patients with vascular dementia also had significant higher levels of TNF-α in 
their cerebrospinal fluid when compared to control individuals. However their plasma 
levels of TNF-α were similar to the control groups (Tarkowski et al, 2003). These results 
point to the CNS has a major site of TNF-a production in overt dementia. An efflux of IL-6 
from the CNS in healthy young subjects has also been reported (Nybo et al, 2002). It 
appears that the CNS not only is able to produce cytokines, but can also contribute to 
the pool of circulating cytokines. Whether the cytokine elevations found in patients with 
Alzeimer’s disease and vascular dementia are actually causing damage or indicate the 
presence of reparatory processes is unanswered. A few studies have shown that 
peripheral administered cytokines do affect human brain functions with negative effects 
on sleep (reviewed by Pollmacher et al, 2002), memory and depression (Reichenberg et 
al,2001). However, at the moment, there are no experimental data available on whether 
small chronic increases in cytokines, like the one seen with ageing, affect human brain 
function. Acute and chronic cytokine increases may have different effects on cognition, 
as small amounts of cytokines seem to be necessary for normal neurological function. 
 
 
6. Inflammatory mediators and sarcopenia 
 
Sarcopenia has been associated with the development of functional disability in the 
elderly (Ferruci at al, 1999) and plays a central role in the frailty syndrome. It has been 
suggested that this syndrome reflects a metabolic imbalance caused by the 
overproduction of catabolic cytokines and the diminished availability of anabolic 
hormones, resulting from ageing itself and the presence of associated chronic conditions 
(Hamerman, 1999). The loss of muscle mass has been associated with systemic low-
grade inflammation. It is also known that TNF-α has effects that may contribute directly 
to sarcopenia: TNF-α can disrupt the differentiation process in cultured muscle cells and 
promotes catabolism in mature muscle cells. It also induces apoptosis through the 
triggering of death domain receptors that are upregulated in the aged muscle cells 
(Roubenoff, 2003). TNF-α also causes increased basal energy expenditure, anorexia 
and loss of muscle and bone mass in vivo (Goodman,1991). Since skeletal muscle is the 
primary site for glucose and triglyceride disposal (Dinneen et al, 1992; Lithell et al, 1981) 
and the predominant determinant of metabolic rate (Zurlo et al, 1994), age-associated 
muscle loss may also contribute to peripheral insulin resistence, dyslipidemia and 
increased adiposity. There is no simple mechanism to explain age-associated muscle-
loss. Skeletal muscle mitochondrial and contractile protein synthetic rates decline with 
age (Rooyackers et al, 1996; Yarasheski et al, 1993), accounting for some of the muscle 
loss and decrease of functional capacity. Plasma levels of TNF-α and other cytokines (as 
previously mentioned) also increase with ageing. An increase in TNF-a, especially if it 
were to occur in skeletal muscle could play a role in the progressive muscle loss of 
advancing age. In a study with frail very elderly subjects (Greiwe et al, 2001), higher 
levels of TNF-α mRNA and protein were observed in muscle tissue from elderly 
compared to young adults and muscle protein synthesis was inversely related to the 
local levels of TNF-α in skeletal muscles. In a recent study by Plomgaard et al, 
(Plomgaard et al, 2005), immunohistochemistry analysis of biopsies from the triceps, 
vastus and soleus muscles, demonstrated that TNF-α and IL-18 were solely expressed 
by type II fibers, whereas the expression of IL-6 was more prominent in type I fibers. 
With age, TNF-α expression is increased predominantly in the vastus lateralis muscle 
(predominantly type II) when compared to the soleus muscle (Philips and 
Leeuwenburgh, 2005). These finding support the idea that TNF-α levels are important in 
the circulation but also within the muscle tissue. Furthermore, it has also been 
demonstrated that IL-18 also plays a role in apoptosis and tissue destruction (Finotto et 
al, 2004).  
The role of IL-6 in sarcopenia is controversial. Although studies have reported that IL-6 is 
strongly associated with functional disability and loss of muscle mass (Ferrucci et al, 
1999; Ferrucci et al, 2002; Visser et al, 2002), experimental studies have not been able 
to link IL-6 to sarcopenia. It is possible that IL-6 acts as a surrogate marker of TNF-α 
because the production of both cytokines is closely related: TNF-α stimulates the 
production of IL-6 and in return IL-6 inhibits the transcription of TNF-α and stimulates the 
production of anti-inflammatory cytokines and the shedding of TNF-R. Age-related 
sarcopenia has also been shown to be partly reversed by exercise. Resistance training 
of frail very elderly people resulted in decreased levels of TNF-α in skeletal muscles 
(Greiwe et al, 2001) and muscle strength after resistance training was inversely 
correlated with baseline levels of sTNF-R indicating that the gain of muscle strength was 
negatively influenced by activities in the TNF system (Bruunsgaard et al, 2004). sTNF-R 
bind TNF-a with high affinity and may act as inhibitors or carriers of TNF-α, prolonging its 
biological effects (Richards et al, 1995). sTNF-R  are more stable in the plasma then 
TNF-a and are often a more consistent marker of activity in the TNF system then the 
plasma levels of TNF-α (Richards et al, 1995). 
 
 
7. Cytokine responses to sepsis and exercise 
 
In view of the previously discussed it is important to understand how the inflammatory 
system reacts to injury and to exercise. In sepsis and experimental models of sepsis, the 
cytokine cascade consists of (named in order) TNF-α, IL.1β, IL-6, IL-1ra, sTNF-R and IL-
10 (Akira et al, 1993). The first two are produced locally and are usually referred as 
proinflammatory cytokines (Dinarello, 1992). TNF-α and IL-1β stimulate the production of 
IL-6, which as been classified both as a pro and an anti-inflammatory cytokine (Tilg et al, 
1997). The cytokine response to exercise is different from that elicited by infections, 
TNF-α and IL-1β, usually do not increase with exercise (Febbraio and Pedersen, 
2002;Pedersen and Hoffman-Goetz, 2000; Suzuki et al, 2002). Typically, IL-6 is the first 
cytokine present in the circulation during exercise, it’s levels increasing exponentially (up 
to 100-fold) in response to exercise and declining in the postexercise period (Febbraio 
and Pedersen, 2002; Pedersen and Hoffman-Goetz, 2000; Suzuki et al, 2002). 
Increased circulating levels of anti-inflammatory cytokines and cytokine inhibitors such 
as IL-1ra and sTNF-R in response to exercise are also found (Ostrowski et al, 1999; 
Ostrowski et al, 2000). In summary exercise provokes initially an increase in IL-6, 
followed by an increase in IL-1ra and IL-10. The appearance of IL-6 in the circulation is 
the most marked and it precedes that of the other cytokines. 
 
 
8. IL-6 response to exercise 
 
A marked increase in circulating levels of IL-6 after exercise without muscle damage has 
been a most consistent finding in exercise literature (reviewed by Febbraio and 
Pedersen, 2002; Pedersen and Hoffman-Goetz, 2003; Pedersen et al, 2003; Pedersen 
et al, 2001). Plasma IL-6 increases are related to exercise intensity, duration, the mass 
of muscle recruited and individual endurance capacity (reviewed by Febbraio and 
Pedersen, 2002; Pedersen and Hoffman-Goetz, 2003; Pedersen et al, 2003; Pedersen 
et al, 2001). Il-6 mRNA is upregulated by the contracting skeletal muscle (Febbraio et al, 
2003; Nieman et al, 2003; Steensberg et al, 2001) and it’s transcriptional rate is 
markedly enhanced by exercise (Keller et al, 2001). It has also been demonstrated that 
the IL-6 protein is expressed in contracting muscle fibers (Penkowa et al, 2003; Hiscock 
et al, 2004) and released (Steensberg et al, 2002) from skeletal muscle during exercise 
whereas this is not the case for TNF-α (Steensberg et al, 2002; Steensberb et al, 2000). 
Even moderate exercise seems to have major effects on muscle derived IL-6. When a 
group of young healthy subjects performed 3h of dynamic two-legged knee-extensor 
exercise at 50% of their individual maximal power output a 16-fold increase in IL-6 
mRNA and a 20-fold increase in plasma IL-6 was observed (Fischer et al, 2004). When 
the same model was applied in healthy elderly subjects, even higher amounts of IL-6 
were released from the working muscle (Pedersen et al, 2001).  
Carbohydrate ingestion has been shown to attenuate the elevation of plasma IL-6 during 
both running and cycling (Nehlsen-Canarella et al, 1997; Nieman et al, 1998) whereas 
low muscle glycogen concentration enhances IL-6 mRNA and transcription rate (Keller et 
al, 2001; Steensberg et al, 2001). Preexercise intramuscular glycogen content appears 
to be an important stimulus for the IL-6 gene transcription with muscle derived IL-6 acting 
as an energy sensor. Muscle-derived IL-6 is regulated by an autocrine mechanism 
(Keller et al, 2003) as shown by the increase in the IL-6 gene expression after infusion of 
rhIL-6 in humans.  
Small amounts of IL-6 are also produced and released by the adipose tissue (Lyngso et 
al, 2002), and some studies indicate that the brain (Nybo et al, 2002) and the peritendon 
tissue (Landberg et al, 2002) may also release IL-6 in response to exercise. Monocytes 
do not seem to major contributors to the IL-6 response to exercise (Moldoveanu et al, 
2000; Starkie et al, 2001). Although the precise biological action of muscle-derived IL-6 
is not known yet, current data suggests that IL-6 released from the contracting muscle 
during exercise acts in a hormone-like manner to mobilize extracellular substrates and 
augment substrate delivery during exercise. 
 
 
9. Anti-inflammatory effects of exercise induced cytokines. 
 
Il-6 seems to have some anti-inflammatory effects. It inhibits TNF-α and IL-1 production, 
stimulates the production of IL-1ra and IL-10 (Steensberg et al, 2003a). It also stimulates 
the release of soluble TNF-α receptors (Tilg et al, 1997) and induces the production of 
the hepatocyte-derived acute phase proteins, many of which have anti-inflammatory 
properties (Akira and Kishimoto, 1992). IL-6 has been shown to inhibit 
lipopolysaccharide (LPS)-induced TNF-a production in cultered human monocytes and in 
the human U937 cell line (Schindler et al, 1990). IL-6 knockout mice show markedly 
elevated levels of TNF-α (Matthys et al, 1995) indicating that IL-6 has a regulatory effect 
on TNF-α levels. In addition, rhIL-6 infusion in healthy young adults inhibits the 
endotoxin-induced increase in circulating levels of TNF-α (Starkie et al, 2003b). 
IL-10 has been shown to inhibit the production of IL-1α, IL-1β, TNF-α and IL-8 (Moore et 
al, 1993). These cytokines are involved in the activation and recruitment of granulocytes, 
monocytes/macrophages, T, B and NK cells to the sites of inflammation. IL-10 is also 
able to suppress cytokine synthesis in LPS stimulated human mononuclear cells by 
inhibiting the transcription of the cytokines genes (Wang et al, 1994). IL-10 is also able to 
prevent cytokine protein synthesis by posttranscriptional mechanisms (mRNA 
degradation) as shown in LPS stimulated human macrophages where the release of IL-
1a, IL-b and TNF-a release was inhibited when IL-10 was added to the cells (Bogdan et 
al, 1992). Thus, IL-10 seems to play an important role in orchestrating the inflammatory 
reaction, mainly in what concerns the activation of the monocytes/macrophage cells. 
The IL-1ra molecule acts by inhibiting signal transduction into the cells by binding to the 
IL-1 receptors. IL-1ra binds to the IL-1 receptor complex does not induce any intracellular 
response (Dinarello, 2000). IL-1ra is also an acute phase protein because both cultured 
human hepatocytes and human hepatoma cell line HepG2 produce IL-1ra after IL-6 
stimulation (Gabay et al, 1997). 
CRP levels also increase after long duration exercise and it has been shown to induce 
the release of anti-inflammatory cytokines by circulating monocytes and to suppress the 
synthesis of proinflammatory cytokines in tissue macrophages (Pedersen and Hoffman-
Goetz, 2000; Pue et al, 1996). 
 
 
10. Anti-inflammatory effects of exercise 
 
Cross-sectional studies have demonstrated an association between physical inactivity 
and low-grade systemic inflammation in healthy elderly people (Abramson and 
Vaccarino, 2002; Geffken et al, 2001; Mattusch et al, 2000; Wannamethee et al, 2002).  
In order to access if  acute exercise induced a true anti-inflammatory response, Starkie 
et al (Starkie et al, 2003) developed a model for “low-grade inflammation” in which they 
injected a low dose of Escherichia coli endotoxin in healthy volunteers, who had either 
been resting, rode a bicycle for 3h or were infused with rhIL-6 for 3h. In the control group 
the TNF-α plasma levels increased significantly in response to the endotoxin while in the 
other two groups the TNF-α response was totally attenuated. Both exercise and rhIL-6 
infusion, at physiological concentrations, were able to inhibit endotoxin-induced TNF-
α production in humans. This paper provided the first experimental evidence of exercise 
mediated anti-inflammatory activity and suggests that the mechanism include IL-6, which 
is produced and released from exercising muscles. This was further supported by a 
study in TNF-R knockout mice (Keller et al, 2004) that demonstrated that exercise 
normalised the overexpression of TNF-α in these mice. Another study demonstrated that 
IL-6 deficient mice developed mature-onset obesity and insulin resistence, which was 
reversed by the administration of IL-6 (Wallenius et al, 2002). So lack of IL-6 caused 
insulin resistance. Given the fact that TNF-α induces insulin resistance, exercise may 
enhance insulin sensitivity through suppression of TNF-α production.  Another important 
finding was the fact that after a progressive resistance exercise training program of 
3days/week for 3 months, with healthy young and frail elderly subjects, muscle TNF-α 
mRNA and protein levels decreased in the exercising group but did not change in the 
control group (Greiwe et al, 2001). Thus exercise seems to suppress skeletal muscle 
TNF-α expression. 
It is possible, that with regular exercise, the anti-inflammatory effects of an acute bout of 
exercise will protect against chronic systemic low-grade inflammation. This long term 
effect of exercise may be ascribed to the anti-inflammatory response elicited by an acute 
bout of exercise, which is partly mediated by muscle-derived IL-6. IL-6 also stimulates 
lipolysis as well as fat oxidation. In general the plasma cytokines found following 
exercise induce a strong anti-inflammatory effect and may offer protection against TNF-
induced insulin resistance.  
It appears that the anti-inflammatory cytokines produced and released by the skeletal 
muscle may be involved in mediating the health beneficial effects of exercise and play 
important roles in the protection against the diseases associated with low-grade 
inflammation. 
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